ObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.com
by Kim Johansen · The Markets DailyStockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV – Free Report) in a research report released on Friday. The brokerage issued a hold rating on the stock.
ObsEva Stock Performance
ObsEva has a 1-year low of $0.08 and a 1-year high of $2.14. The stock has a market cap of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68.
ObsEva Company Profile
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Featured Articles
- Five stocks we like better than ObsEva
- What is a Death Cross in Stocks?
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- What Are the FAANG Stocks and Are They Good Investments?
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- 10 Best Airline Stocks to Buy
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors